Home / Health / AstraZeneca Cancer Drug Fails Key Trial Goal
AstraZeneca Cancer Drug Fails Key Trial Goal
12 Sep
Summary
- AstraZeneca's breast cancer drug Etcamah failed a key trial.
- The drug did not meet its primary goal of improving survival.
- This marks a setback for the recently approved treatment.
AstraZeneca announced a significant setback for its breast cancer drug, Etcamah. A late-stage clinical trial revealed that the drug failed to meet its primary objective of improving progression-free survival.
When tested in combination with palbociclib, Etcamah demonstrated only a numerical improvement in patients with a specific form of advanced breast cancer who had not previously received treatment. The company indicated that further trial data would be shared in due course.
This outcome contrasts with the recent accelerated approval granted by the U.S. Food and Drug Administration for Etcamah. The approval allows its use in conjunction with specific targeted cancer medicines, known as CDK4/6 inhibitors.
